Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD

31 Dec 2025, 07:04 by Renee Jackson · The Cerbat Gem

Lee Johnson Capital Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 22,606 shares of the biopharmaceutical company’s stock, valued at approximately $2,509,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $30,000. Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Finally, Kilter Group LLC acquired a new position in Gilead Sciences during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on GILD shares. UBS Group upgraded Gilead Sciences to a “hold” rating in a research note on Thursday, December 4th. Truist Financial initiated coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They set a “buy” rating and a $140.00 price target on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Daiwa Capital Markets upped their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.68.

Get Our Latest Stock Report on GILD

Gilead Sciences Trading Down 1.4%

Shares of Gilead Sciences stock opened at $123.18 on Wednesday. The stock has a market cap of $152.83 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The firm has a fifty day moving average price of $122.97 and a 200 day moving average price of $116.89. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the sale, the chief financial officer owned 153,503 shares of the company’s stock, valued at $18,727,366. This trade represents a 1.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 136,257 shares of company stock valued at $16,855,192 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.